GSMA Expands Mobile 360 Series of Events in 2016
The GSMA today announced the schedule and locations for the 2016 GSMA Mobile 360 Series, a regional thought leadership conference series for executives in the mobile industry, as well as key regulatory and government representatives. This year, the GSMA is again expanding the scope of the Mobile 360 Series of conferences, with seven conferences around the world, including one focused specifically on privacy and security issues.
“We’re excited to further broaden the Mobile 360 Series to include additional geographies and also to focus on specific subject areas, with the addition of Mobile 360 – India and Mobile 360 – Privacy & Security,” said Michael O’Hara, Chief Marketing Officer, GSMA. “The Mobile 360 Series conferences provide a focused forum through which attendees can not only explore the most pressing issues facing the mobile industry, but engage in a substantive dialogue that will help drive action.”
In 2016, the GSMA will host the following Mobile 360 Series conferences:
Mobile 360 Series Conference
|Mobile 360 Series – Privacy & Security||The Hague, Netherlands||10-11 May|
|Mobile 360 Series – Europe||Brussels, Belgium||14 June|
|Mobile 360 Series – Africa||Dar es Salaam, Tanzania||26-28 July|
|Mobile 360 Series – Latin America||Mexico City, Mexico||20-22 September|
|Mobile 360 Series – Middle East||Dubai, United Arab Emirates||17-18 October|
|Mobile 360 Series – India||New Delhi, India||26 October|
|GSMA Mobility Live! – North America||Atlanta, United States||1-2 November|
Introducing Mobile 360 Series – Privacy & Security
The first event in the 2016 Mobile 360 Series, Mobile 360 Series – Privacy & Security, will be held at the Hilton The Hague. In cooperation with The Hague Security Delta and The Municipality of The Hague, Mobile 360 – Privacy & Security will explore the state of digital security and data privacy today and examine best practices across a variety of industries. This two-day event will include a combination of keynote presentations, panel discussions, technology demonstrations and in-depth case studies that address the growing importance of privacy and security across the globe.
Speakers currently confirmed to present in the conference include:
- Jim Bailey, Senior Managing Director, Accenture Mobility
- Evelyn Tjon-En-Fa, Partner, Bird & Bird
- Thomas Whipp, CISO, Charles Taylor PLC
- Alvin Khodabaks, Partner, Clifford Chance
- Mats Granryd, Director General, GSMA
- Gert-Jan Schenk, Vice President EMEA, Lookout
- Rimma Perelmuter, CEO, Mobile Ecosystem Forum
- Deputy Mayor Ingrid van Engelshoven, Alderman for Knowledge Economy, International, Youth and Education, Municipality of The Hague
- Karsten Nohl, Chief Scientist, Security Research Labs
- Chris Roberts, CSH and Security Consultant, Sentinel Global
- Dr. Ulf Gartzke, Managing Partner and Founder, Spitzberg Partners LLC
- Chris Roberts, CSH and Security Consultant, Sentinel Global
- Oscar Mancebo Ortiz, Head of Mobile Connect, Telefónica Group
- Charl van Niekerk, CEO, Thuthukani Technology Solutions
- Oliver Blower, CEO, VoxSmart
For additional information on Mobile 360 – Privacy and Security, including speaking and sponsorship opportunities, as well as how to attend, visit www.mobile360series.com/privacy-security/.
New Developments for North America Event
The Mobile 360 Series returns again to Atlanta, with the city hosting the North American event 1-2 November 2016. In a very exciting development, the GSMA and the Metro Atlanta Chamber have joined forces to create GSMA Mobility Live! – North America. This new conference merges the previous Mobile 360 – North America and Mobility LIVE! events to deliver a platform for exploring the key trends impacting the mobile industry as well as adjacent industry sectors.
“We are pleased to be partnering even more closely with the Metro Atlanta Chamber in creating a dynamic event that will attract mobile industry leaders from not only the greater Atlanta area but across all of North America,” commented O’Hara.
Further information on the entire Mobile 360 Series of events is available at www.mobile360series.com/. Follow developments and updates on Mobile 360 (#mobile360) on Twitter @GSMA and on Facebook www.facebook.com/Mobile360Series.
About the GSMA
The GSMA represents the interests of mobile operators worldwide, uniting nearly 800 operators with more than 250 companies in the broader mobile ecosystem, including handset and device makers, software companies, equipment providers and internet companies, as well as organisations in adjacent industry sectors. The GSMA also produces industry-leading events such as Mobile World Congress, Mobile World Congress Shanghai and the Mobile 360 Series conferences.
For more information, please visit the GSMA corporate website at www.gsma.com. Follow the GSMA on Twitter: @GSMA.
Om Business Wire
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
ADC Therapeutics Presents Interim Phase I Data from its Novel Antibody-Drug Conjugate ADCT-40211.12.2017 06:00 | Pressemelding
ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced clinical data from two ongoing Phase I clinical trials evaluating ADCT-402 (loncastuximab tesirine or “Lonca-T”) in important subtypes of lymphoma and leukemia. The data were presented at the 59th American Society of Hematology (ASH) Annual Meeting in Atlanta, USA. 1. Interim results of a Phase I open label, single agent, dose-escalating study of ADCT-402 evaluating tolerability, safety, pharmacokinetics and efficacy in patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma Dr. Brad Kahl, M.D., Professor for Medical Oncology at the Washington University School of Medicine in St. Louis, said: “A significant number
GA Telesis Launches Leveraged Finance Group with the Appointments of David Lloyd and Nolan Heske11.12.2017 05:01 | Pressemelding
GA Telesis, LLC (“GAT”) announces the launch of its Leveraged Finance Group (“LFG”) to provide secured aircraft financing for lessors, investors, and airlines. GAT has appointed David Lloyd and Nolan Heske as Managing Directors of LFG to pursue the development, execution and growth of this strategy. The LFG management team has over 35 years of combined experience in the aircraft and transportation finance sector. Prior to joining GAT, Mr. Lloyd and Mr. Heske cofounded Air Funding in 2016 to provide an alternative source of direct lending on commercial aircraft to lessors and airlines. Prior to Air Funding, David Lloyd spent 12 years at Carlson Capital as Head of Credit, Airlines & Aerospace. Mr. Lloyd was the group founder and was responsible for a portfolio with peak assets of $475 million. Mr. Lloyd also held executive positions at Credit Suisse and Chase Securities. No
AstraZeneca’s Calquence (acalabrutinib) Shows Potential in Chronic Lymphocytic Leukaemia Trials10.12.2017 22:45 | Pressemelding
AstraZeneca and Acerta Pharma, its haematology research and development centre of excellence, today presented results from the Phase Ib/II ACE-CL-003 clinical trial (Abstract #432) and updated results from the Phase I/II ACE-CL-001 (Abstract #498) clinical trial that are testing Calquence (acalabrutinib) alone and in combination for the treatment of chronic lymphocytic leukaemia (CLL) in multiple treatment settings. The findings were presented during two oral sessions at the 59th American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA. Sean Bohen, Executive Vice President, Global Medicines Development and Chief Medical Officer at AstraZeneca, said: “These data add to the growing body of evidence that supports the potential of Calquence in the treatment of chronic lymphocytic leukaemia, a life-threatening disease that affects tens of thousands of people aroun
Celgene Corporation and bluebird bio Announce Updated Results from Ongoing Multicenter Phase 1 Study of bb2121 Anti-BCMA CAR T Cell Therapy in Patients with Late Stage Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting10.12.2017 15:30 | Pressemelding
Celgene Corporation (NASDAQ: CELG) and bluebird bio, Inc. (Nasdaq: BLUE) today announced that updated results from the ongoing CRB-401 Phase 1 clinical study of bb2121, an investigational anti-B-cell maturation antigen (BCMA) CAR T cell therapy, in 21 patients with late-stage relapsed/refractory multiple myeloma will be presented in an oral presentation at the American Society of Hematology (ASH) Annual Meeting in Atlanta, Georgia. The objective of this Phase 1 dose-escalation study is to evaluate safety and efficacy of bb2121 and determine a recommended Phase 2 dose. “Celgene has a longstanding commitment to patients with multiple myeloma through our extensive research efforts in this deadly blood cancer,” said Nadim Ahmed, President, Hematology and Oncology for Celgene. “Looking ahead, we see BCMA as an important target in this disease and we believe bb2121 has the potenti
Kite Announces Long-Term Data From Pivotal ZUMA-1 Study of Yescarta™ (Axicabtagene Ciloleucel) in Patients With Refractory Large B-cell Lymphoma10.12.2017 15:30 | Pressemelding
Kite, a Gilead Company (Nasdaq: GILD), announced long-term follow-up data from the pivotal ZUMA-1 study of Yescarta™ (axicabtagene ciloleucel) in patients with refractory large B-cell lymphoma. With a minimum follow-up of one year after a single infusion of Yescarta (median follow-up of 15.4 months), 42 percent of patients continued to respond to therapy, including 40 percent with a complete remission. Detailed results from this updated analysis were simultaneously presented at the Annual Meeting of the American Society of Hematology (ASH) in Atlanta and published in The New England Journal of Medicine. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20171210005072/en/ Yescarta is the first chimeric antigen receptor T (CAR T) cell therapy to be approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult
Takeda and Seattle Genetics to Present Positive Data from Phase 3 ECHELON-1 Clinical Trial Evaluating ADCETRIS® (brentuximab vedotin) in Frontline Advanced Hodgkin Lymphoma10.12.2017 13:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE:4502) and Seattle Genetics, Inc. (NASDAQ: SGEN) today announced that data from the Phase 3 ECHELON-1 clinical trial evaluating ADCETRIS (brentuximab vedotin) as part of a frontline combination chemotherapy regimen in untreated advanced classical Hodgkin lymphoma will be presented in the Plenary Scientific Session at the 59th American Society of Hematology (ASH) annual meeting on Sunday, December 10, 2017. The data were also simultaneously published online in the New England Journal of Medicine and will be published in the print edition on January 25, 2017. Topline data were reported in June 2017 demonstrating the ECHELON-1 trial met its primary endpoint of a statistically significant improvement in modified progression-free survival (modified PFS) per Independent Review Facility (IRF) versus the control arm. ADCETRIS is an antibody-drug con
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom